Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This drug is a small molecule experimental compound with the molecular formula C20H33N5O5S and a molecular weight of approximately 455.6 g/mol[1][6]. It belongs to the class of n-acyl-alpha amino acids and derivatives[6]. The mechanism of action is not explicitly described in available sources; however, its structure suggests potential activity as an enzyme inhibitor or modulator due to the presence of thiazole and hydroxamic acid moieties. There is no publicly available information on primary indication or clinical development status for this specific compound.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on (2r,3r)-n^1^-[(1s)-2,2-dimethyl-1-(methylcarbamoyl)propyl]-n^4^-hydroxy-2-(2-methylpropyl)-3-{[(1,3-thiazol-2-ylcarbonyl)amino]methyl}butanediamide.